In The News
2020 - 01 - 09
Transcenta tops off $100M series B+
Transcenta Holding Ltd. raised $20 million in a second tranche of its series B+, bringing the total amount raised in the round to $100 million. CR-CP Life Science Fund and Fortune Capital led the round, which saw participation by new investors Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group and existing investors Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners, Sequoia Capital China and ARCH Venture Partners.
In Conversation | Xueming Qian – CEO & Co-Founder, Transcenta
Putting Biologics on the Fast Lane
Industrialization of Highly Intensified Connected/Continuous Biomanufacturing Platform (HiCB) to Address Patient and Business Needs
A CTO's Journey Into Continuous Biomanufacturing
TST001 Under Evaluation in Locally Advanced or Metastatic Solid Tumors
BioPharm International:Moving Closer to End-to-End Continuous Bioprocessing